Filing Details

Accession Number:
0001214659-18-003059
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-04-26 18:00:30
Reporting Period:
2018-03-09
Accepted Time:
2018-04-26 18:00:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576263 Mirati Therapeutics Inc. MRTX Pharmaceutical Preparations (2834) 462693615
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1599324 Jamie Christensen C/O Mirati Therapeutics, Inc.
9393 Towne Centre Drive, Ste 200
San Diego CA 92121
Svp, Chief Scientific Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-03-09 7,000 $17.41 9,877 No 4 M Direct
Common Stock Acquisiton 2018-03-09 7,500 $21.51 17,377 No 4 M Direct
Common Stock Acquisiton 2018-03-09 7,500 $24.99 24,877 No 4 M Direct
Common Stock Disposition 2018-03-09 22,000 $33.00 2,877 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2018-03-09 7,000 $0.00 7,000 $17.41
Common Stock Employee Stock Option (Right to Buy) Disposition 2018-03-09 7,500 $0.00 7,500 $21.51
Common Stock Employee Stock Option (Right to Buy) Disposition 2018-03-09 7,500 $0.00 7,500 $24.99
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
18,936 2024-05-20 No 4 M Direct
15,000 2025-02-03 No 4 M Direct
45,000 2026-01-21 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2017.
  2. This transaction was executed in multiple trades at prices ranging from $33.00 to $33.005. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to
  3. 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter